Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18904628 | ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD | October 2024 | July 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18896098 | ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND | September 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18802353 | COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAME | August 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18787110 | IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF | July 2024 | April 2025 | Allow | 9 | 2 | 1 | No | No |
| 18731223 | LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONS | May 2024 | January 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18656166 | ANTIBODIES TARGETING LIV-1 AND USES THEREOF | May 2024 | August 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18648976 | ANTIBODY AGAINST ADVANCED GLYCATION END PRODUCTS AND USE THEREOF | April 2024 | September 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18411436 | ANTI-CD37 ANTIBODY-DRUG CONJUGATE | January 2024 | July 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18393436 | VACCINIA VIRUS RECOMBINANT A33R PROTEIN AND KIT FOR DIAGNOSING ANTIBODIES AGAINST ORTHOPOXVIRUS COMPRISING THE SAME | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18511591 | ANTI-B7H3 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | November 2023 | June 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18366183 | METHOD OF TREATING POST-TRAUMATIC STRESS DISORDER | August 2023 | May 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18225567 | PROTEIN-ANTIVIRAL COMPOUND CONJUGATES | July 2023 | February 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18320869 | ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | May 2023 | March 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18118105 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | March 2023 | December 2024 | Allow | 21 | 2 | 0 | No | No |
| 18117089 | ANTIBODY-DRUG CONJUGATE | March 2023 | June 2024 | Allow | 16 | 0 | 0 | No | No |
| 18175148 | AMANITIN CONJUGATES | February 2023 | September 2024 | Allow | 19 | 1 | 0 | No | No |
| 18160012 | COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B-TARGETED THERAPY | January 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18080079 | Methods For Treating Hypersomnia | December 2022 | October 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18072963 | PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS | December 2022 | March 2025 | Allow | 27 | 1 | 0 | No | No |
| 17990485 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | November 2022 | October 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17988595 | POLYMER LINKERS AND THEIR USES | November 2022 | February 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 17924253 | COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENEIC CELLS USING SIMIAN ICP47 AND VARIANTS THEREOF | November 2022 | May 2025 | Abandon | 31 | 0 | 0 | No | No |
| 17822638 | Conjugates for Targeted Cell Surface Editing | August 2022 | April 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17878049 | CELL SURFACE ANCHORING ANTIGEN CONJUGATES TO TREAT CANCER | August 2022 | May 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17814728 | ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS | July 2022 | November 2024 | Allow | 27 | 2 | 0 | No | No |
| 17793276 | MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF | July 2022 | May 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17859015 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | July 2022 | November 2024 | Allow | 28 | 2 | 0 | No | No |
| 17835041 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | June 2022 | June 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17835081 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | June 2022 | February 2025 | Allow | 32 | 2 | 1 | No | No |
| 17835395 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | June 2022 | May 2025 | Allow | 35 | 1 | 1 | No | No |
| 17835311 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | June 2022 | July 2025 | Allow | 37 | 2 | 1 | No | No |
| 17830781 | DELTA-OPIOID RECEPTOR TARGETED AGENT FOR MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER | June 2022 | August 2024 | Allow | 27 | 2 | 0 | No | No |
| 17749953 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | May 2022 | March 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17733974 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | April 2022 | March 2025 | Allow | 35 | 0 | 1 | No | No |
| 17697583 | B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES | March 2022 | April 2025 | Allow | 37 | 3 | 1 | Yes | Yes |
| 17553745 | ANTIBODY DRUG CONJUGATES | December 2021 | May 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17549586 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | December 2021 | June 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17546706 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | December 2021 | October 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17531343 | GLYCOSIDE DUAL-CLEAVAGE LINKERS FOR ANTIBODY-DRUG CONJUGATES | November 2021 | August 2024 | Allow | 33 | 3 | 0 | Yes | No |
| 17598064 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | September 2021 | April 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17469799 | METHODS FOR MANUFACTURING PHTHALOCYANINE DYE CONJUGATES AND STABLE CONJUGATES | September 2021 | April 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 16644842 | ANTI-MESOTHELIN ANTIBODY AND ANTIBODY DRUG CONJUGATE THEREOF | August 2021 | August 2024 | Allow | 53 | 1 | 0 | No | No |
| 17431059 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR NEOVASCULARIZATION | August 2021 | April 2025 | Allow | 44 | 1 | 1 | No | No |
| 17424528 | COMPOUND FOR PREPARATION OF ANTIBODY-PAYLOAD CONJUGATE AND USE THEREOF | July 2021 | January 2025 | Allow | 42 | 2 | 0 | No | No |
| 17374756 | ANTIBODY DRUG CONJUGATES WITH ENZYMATICALLY CLEAVABLE GROUPS | July 2021 | July 2024 | Allow | 36 | 3 | 0 | Yes | No |
| 17358306 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | June 2021 | June 2024 | Allow | 35 | 2 | 1 | No | No |
| 17309778 | CONTROLLED FUCOSYLATION OF ANTIBODIES | June 2021 | February 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17341606 | PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17331290 | Glycan-Interacting Compounds and Methods of Use | May 2021 | May 2025 | Abandon | 47 | 0 | 2 | No | No |
| 17295420 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | May 2021 | September 2024 | Allow | 40 | 2 | 0 | No | No |
| 17291141 | FILTERABLE DUOCARMYCIN-CONTAINING ANTIBODY-DRUG CONJUGATE COMPOSITIONS AND RELATED METHODS | May 2021 | August 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17290694 | ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17284388 | COMPOUNDS AND THERAPEUTIC USES THEREOF | April 2021 | January 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17210081 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | March 2021 | March 2025 | Allow | 48 | 2 | 1 | No | Yes |
| 17044659 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | March 2021 | January 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17276324 | ANTI-LILRB2 ANTIBODIES AND METHODS OF USE THEREOF | March 2021 | July 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17176326 | PROCESS FOR PRODUCING ALKALI TAURINATE | February 2021 | April 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17262157 | NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAME | January 2021 | July 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17260901 | LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE | January 2021 | August 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17258250 | PROTEIN-BASED MICELLES FOR THE DELIVERY OF HYDROPHOBIC ACTIVE COMPOUNDS | January 2021 | June 2025 | Abandon | 54 | 0 | 2 | No | No |
| 17135946 | METHODS FOR TREATING AND REDUCING TRAUMATIC BRAIN INJURY- ASSOCIATED IMPAIRMENTS USING SGP130 | December 2020 | April 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 16945163 | USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)-KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN | July 2020 | June 2025 | Abandon | 58 | 4 | 1 | No | Yes |
| 16941383 | LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE | July 2020 | March 2025 | Abandon | 55 | 1 | 1 | No | No |
| 16921528 | Modified Antibody, Antibody-Conjugate and Process For The Preparation Thereof | July 2020 | August 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16486862 | CD20-TARGETED ANTIBODY COUPLING PHARMACEUTICAL PREPARATION | February 2020 | February 2025 | Allow | 60 | 5 | 0 | No | No |
| 16639499 | PROGRAMMABLE DENDRITIC DRUGS | February 2020 | February 2025 | Allow | 60 | 6 | 1 | No | No |
| 16694283 | METHOD OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) STABILIZATION | November 2019 | July 2024 | Allow | 56 | 6 | 0 | Yes | No |
| 16348749 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | May 2019 | March 2025 | Allow | 60 | 8 | 1 | Yes | No |
| 16302270 | USE OF GLUTAMATE MODULATING AGENTS WITH IMMUNOTHERAPIES TO TREAT CANCER | November 2018 | January 2022 | Abandon | 38 | 6 | 1 | Yes | No |
| 16096631 | PYRROLOBENZODIAZEPINE CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER | October 2018 | September 2019 | Allow | 11 | 1 | 0 | No | No |
| 16095262 | DIMERIC COMPOUNDS | October 2018 | April 2019 | Allow | 5 | 0 | 0 | Yes | No |
| 16162158 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | October 2018 | December 2018 | Allow | 9 | 0 | 0 | Yes | No |
| 16076588 | PYRROLOBENZODIAZEPINE CONJUGATES | August 2018 | February 2020 | Allow | 18 | 2 | 0 | No | No |
| 15765685 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | April 2018 | November 2024 | Abandon | 60 | 8 | 1 | Yes | No |
| 15764100 | CRYSTALLINE AND AMORPHOUS FORMS OF 17-ALPHA-HYDROXYPROGESTERONE CAPROATE | March 2018 | October 2019 | Allow | 19 | 1 | 1 | Yes | No |
| 15678281 | OXYGEN GENERATING BIOMATERIAL | August 2017 | September 2019 | Allow | 25 | 2 | 0 | No | No |
| 15527129 | COMBINATIONS OF PROSTAGLANDINS AND NITRIC OXIDE DONORS | May 2017 | December 2019 | Allow | 31 | 4 | 0 | Yes | No |
| 15514928 | PREDICTION OF RESPONSE TO PARP INHIBITORS AND COMBINATIONAL THERAPY TARGETING C-MET AND PARP1 | March 2017 | June 2019 | Allow | 26 | 0 | 1 | Yes | No |
| 13499724 | PROCESS FOR PREPARATION OF DIETHYLENETRIAMINEPENTAACETIC ACID DERIVATIVE, AND DIETHYLENETRIAMINEPENTAACETIC ACID DERIVATIVE | April 2012 | May 2013 | Allow | 14 | 1 | 0 | No | No |
| 13409657 | PROCESS FOR PREPARING POLYISOCYANATES COMPRISING BIURET GROUPS | March 2012 | August 2013 | Allow | 17 | 1 | 1 | No | No |
| 13396884 | SYSTEMS FOR ALKYL ESTER PRODUCTION | February 2012 | February 2013 | Allow | 12 | 1 | 1 | No | No |
| 13368601 | ANHYDRIDE DERIVATIVES OF 2-(S)-(6-METHOXY-2-NAPHTYL)-PROPANOIC ACID, PREPARATION METHOD AND USE THEREOF | February 2012 | August 2013 | Allow | 18 | 1 | 0 | No | No |
| 13341311 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | December 2011 | July 2012 | Allow | 7 | 1 | 0 | No | No |
| 13141325 | PROCESS FOR PRODUCING ACRYLIC ACID | June 2011 | November 2012 | Allow | 17 | 3 | 0 | Yes | No |
| 13059766 | METAL COMPLEX AND MANUFACTURING METHOD THEREFOR | May 2011 | September 2013 | Allow | 30 | 1 | 1 | No | No |
| 13125895 | PROCESS FOR PREPARING ISOCYANATES | April 2011 | March 2013 | Allow | 23 | 0 | 0 | No | No |
| 12741247 | PROCESS FOR THE SYNTHESIS OF A PROPARGYLIC ALCOHOL | March 2011 | September 2011 | Allow | 17 | 0 | 0 | No | No |
| 13038472 | METHOD FOR PRODUCING A PERFLUORO COMPOUND HAVING HYDROXYL GROUPS | March 2011 | April 2013 | Allow | 25 | 2 | 0 | Yes | No |
| 12666773 | Phospholipase A2 Inhibitors and their Use in Treating Neurological Injury and Disease | January 2011 | December 2012 | Allow | 36 | 4 | 0 | Yes | No |
| 12969013 | NATEGLINIDE CRYSTALS | December 2010 | March 2011 | Allow | 3 | 0 | 0 | No | No |
| 12867055 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | October 2010 | February 2012 | Allow | 18 | 0 | 0 | No | No |
| 12908583 | PROCESS FOR THE PREPARATION OF PHENOL | October 2010 | April 2012 | Allow | 18 | 1 | 1 | No | No |
| 12921495 | METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS | September 2010 | April 2012 | Allow | 20 | 1 | 0 | No | No |
| 12918391 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | August 2010 | October 2012 | Allow | 26 | 1 | 0 | No | No |
| 12863033 | METHOD FOR PREPARING (METH)ACRYLIC ANHYDRIDE | August 2010 | September 2011 | Allow | 14 | 0 | 0 | No | No |
| 12823338 | PROCESS FOR PREPARING FORMIC ACID | June 2010 | December 2012 | Allow | 30 | 2 | 0 | No | Yes |
| 12735121 | CARBONYLATION PROCESS FOR THE PRODUCTION OF METHYL ACETATE | June 2010 | February 2013 | Allow | 32 | 1 | 0 | No | No |
| 12735214 | NOVEL COMPOUNDS USEFUL IN THERAPEUTIC AND COSMETIC METHODS | June 2010 | April 2013 | Allow | 34 | 2 | 1 | No | No |
| 12816701 | BIOBASED POLYESTERS | June 2010 | January 2013 | Allow | 31 | 1 | 2 | No | No |
| 12766162 | (3R)-L-MENTHYL 3-HYDROXYBUTYRATE, PROCESS FOR PRODUCING THE SAME, AND SENSATE COMPOSITION COMPRISING THE SAME | April 2010 | March 2013 | Allow | 35 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PUTTLITZ, KARL J.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 47.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner PUTTLITZ, KARL J works in Art Unit 1646 and has examined 303 patent applications in our dataset. With an allowance rate of 93.1%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner PUTTLITZ, KARL J's allowance rate of 93.1% places them in the 80% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by PUTTLITZ, KARL J receive 1.73 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PUTTLITZ, KARL J is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +5.1% benefit to allowance rate for applications examined by PUTTLITZ, KARL J. This interview benefit is in the 30% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 32.2% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 48.1% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 78.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 52.2% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 30.7% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.4% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.